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1. Introduction 
Glaucoma is the second leading cause of visual loss worldwide [1-2]. It is becoming an 
increasing cause of blindness as the world’s population ages, and perhaps presents an even 
greater public health challenge than the first-placed cataract, since the disease is irreversible. 
A recent estimate suggests that roughly 80 million people will be diagnosed with glaucoma 
by 2010, with 4.5 million of those suffering bilateral blindness [3]. Glaucoma is a general 
term for a group of ocular diseases characterized by progressive thinning of the neuroretinal 
rim of the optic nerve head and loss of the retinal nerve fiber layer, together with a 
particular pattern of visual field loss. Primary open-angle glaucoma (POAG) is the most 
common type of glaucoma, with a prevalence rate ranged from 0.5 to 8.8% in different 
population based prevalence studies [4-12]. The exact cause of glaucoma is still elusive yet 
after years of extensive research. Traditionally, elevated intraocular pressure (IOP) has been 
identified as a primary risk factor in this illness and IOP lowering remains the principle and 
the only available treatment. However, factors quite independent of IOP may be responsible 
for glaucoma [13]. Approximately one third to one half of patients with POAG consistently 
have IOPs within the normal range of less than 22 mmHg [14-17], identified as having 
normal tension glaucoma (NTG) [18]. Besides, some glaucoma patients continue to present 
disease progression despite effective lowering of IOP. The Early Manifest Glaucoma Trial 
(EMGT) showed that glaucoma progression rate in the treatment group was 45% as 
compared with 62% in the nontreated control group [19]. In the Collaborative Initial 
Glaucoma Treatment Study (CIGTS), substantial visual field loss occurred in 10.7% of 
medically treated and 13.5% of surgical treated participants during 5 years of follow up [20]. 
It is clear that glaucoma is a multifactorial disease and cannot be prevented or cured by IOP 
reducing therapy alone.  
Risk factors other than IOP elevation may be responsible for glaucoma progression. Several 
large scale trails have found aging, systemic blood pressure, nocturnal hypotension, ocular 
perfusion pressure, migraine, disk hemorrhage, and diabetes to be related to open-angle 
glaucoma (OAG). Vascular dysregulation and blood flow disturbances have been reported 
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as glaucoma is often accompanied by widespread cerebrovascular and systemic 
cardiovascular diseases [21]. Leske and colleagues had presented predictors of OAG disease 
progression in the EMGT trial including lower systolic perfusion pressure, lower systolic 
blood pressure, and cardiovascular disease history [22]. In the Rotterdam eye study, patients 
with an ocular perfusion pressure lower than 50 mmHg had a four times greater risk of 
developing OAG than those with a perfusion pressure of 80 mmHg [23]. The Egna-
Neumarkt study found positive correlations between systemic blood pressure and both the 
diagnosis of OAG and elevated IOP [24]. Recently, perfusion instability, rather than a 
progressive decline in ocular blood flow, has been suggested to contribute to OAG. The 
capacity of an organ to maintain a constant blood flow or nutrient supply in response to 
local vascular parameter changes rely on its autoregulation [25]. Failure of stable blood flow 
regulation may lead to ischemic damage of the optic nerve or retinal ganglion cells. 
Challenges to normal ocular blood flow include increased IOP, fluctuating blood pressure, a 
resultant decrease in ocular perfusion pressure, or a rise in local tissue metabolic demands. 
The proposed underlying medical conditions which may contribute to ocular vascular 
regulatory dysfunction include atherosclerosis, vasospasm, and endothelial dysfunction.  
Atherosclerosis is a chronic progressive vascular disease results from the deposition of 
lipids, inflammatory cells and connective tissue within arterial walls, leading to plaque 
formation and intimal thickening. Over time this results in obstruction to flow, 
compromised perfusion and tissue ischemia [26-27]. Decades ago, the treatment of 
hypercholesterolemia and hypertension was expected to eliminate atherosclerosis and 
cardiovascular diseases. However, this prediction needed revision. Recent research has 
shown that inflammation and endothelial dysfunction play a key role in atherosclerosis. 
Aging, cigarette smoking, hypertension, diabetes, elevated low-density lipoprotein (LDL) 
levels, genetic alterations, elevated plasma homocysteine concentrations, and infectious 
microorganisms were shown to perturb the normal barrier and the secretory function of 
endothelial cells and alter the homeostatic properties of the endothelium [28-29]. The injury 
may initiate an inflammatory response in the artery wall, increase the adhesiveness of the 
endothelium to leukocytes or platelets, induce the endothelium to have procoagulant 
properties, and to form vasoactive molecules, cytokines, and growth factors. With the 
migration of smooth muscle cells which intermixed with macrophages and lymphocytes, a 
fibrous tissue developed overlying a core of lipid and necrotic tissue, the atheroma formed. 
The lesion may intrude the lumen and alter the blood flow [29-30]. Atherosclerosis is now 
clearly an inflammatory disease. Several different inflammatory markers with different 
biologic activities were reported to be involved in increased cardiovascular risk or disease 
progression [31-34]. Among which, C-reactive protein (CRP) was reported an independent 
risk factor for coronary artery disease in healthy population [31-32].  
CRP is a primitive acute phase inflammatory protein released in response to acute injury, 
infection, or other inflammatory stimuli [35]. Discovered in 1930 by Tillet and Frances, CRP 
owes its name to the ability of this protein to precipitate pneumococcal C-polysaccharide in 
the presence of calcium. CRP is known to be produced primarily in the liver, synthesized by 
hepatocytes in response to intermediary inflammatory cytokines particularly IL-6. It reaches 
peak levels quickly in approximately 50 hours, falls once the inflammatory stimulus is 
removed and has a half-life of 18 hours, and is not subject to diurnal variation [36]. Other 
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possible sites of CRP expression include atherosclerotic plaque, normal human artery, heart, 
kidney and adipocytes [37-38]. The CRP levels vary in different age groups and races. 
Woloshin et al. reported the CRP levels in American adults increase from 1.4mg/L at age 20-
30 to 2.7 mg/L at age > 80 [39]. Anand et al. reported that sampling from 4 communities in 
Canada, the CRP level is highest among the aboriginal Americans, followed by south 
Asians, Europeans, and lowest in Chinese [40]. Traditionally, serum CRP levels were 
measured by rate nephelometry, which had a poor sensitivity in detecting concentrations 
below 6 to 10 mg/L. With the introducing of a commercially available latex particle-
enhanced immunoturbidimetric assay, the detecting limit can be lowered to 0.15mg/L, that 
is the so-called high-sensitivity CRP. CRP has recently been proposed as a marker of 
inflammation involved in endothelial dysfunction and atherogenesis [41-42]. Clinical studies 
have shown that elevated CRP levels in healthy populations predict vascular events such as 
myocardial infarction (MI) and stroke, as well as the development of diabetes. The 
guidelines for cardiovascular diseases have recommended using CRP for population 
screening or to monitor treatment [43]. 
In glaucoma, several reports have identified compromised peripheral endothelial cell 
function in patients with NTG and OAG [44-47]. However, a corollary correlation between 
atherosclerosis and OAG has yet to be identified, and very few reports had addressed the 
relationship between CRP and glaucoma. Leibovitch et al. reported that the CRP levels was 
significantly elevated in the patients with NTG [48]. On the other hand, the Rotterdam eye 
study found neither atherosclerosis nor serum CRP to be important risk factors for the 
development of OAG [27]. Su et al. reported that after carefully excluding patients with 
systemic diseases such as diabetes mellitus, hypertension, hypercholesterolemia, ischemic 
heart disease and cerebrovascular accidents, there was no statistically significant difference 
in the CRP levels between NTG, POAG and control subjects. Their finding suggested that 
the previously reported CRP elevation in the NTG patients could possibly be a confounded 
result [49]. Data from the Korean population reported by Choi et al. also supported this 
finding [50]. Certain diseases such as coronary artery disease (CAD), CAD’s associated risk 
factors, and medications such as calcium channel blockers, angiotensin converting enzyme 
inhibitors (ACEIs), lipid lowering drugs, aspirin, nitrate, or hormone replacement therapy 
can affect the CRP level. Therefore, it would be more appropriate to determine the 
association between CRP and glaucoma after excluding those patients with systemic 
diseases [51-56].  
Being a marker of systemic inflammation, how CRP plays a pathogenic role in the vascular 
endothelium is a subject of debate. Previously CRP was believed to be produced exclusively 
in the liver, but recent data suggests that CRP is also produced in human atheroma [38, 57-
58]. CRP was reported to have numerous effects on endothelial cells that could support a 
pro-inflammatory, pro-thrombotic role [59], but some investigators have shown that 
through protecting the eNOS protein expression, CRP may play a compensatory role in the 
arterial endothelium locally during inflammation [60]. Whether CRP is harmful or beneficial 
in the vascular micro-environment and whether it is a cause or a result of endothelial 
dysfunction in glaucoma requires further investigation. The negative results between CRP 
and glaucoma implied that either the systemic CRP level does not reflect its local influence, 
or that the CPR abnormality does not exist in patients with glaucoma. 
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A marker intended for screening, diagnosing, or guiding therapy requires good sensitivity, 
specificity and predictive values. Sometimes markers can be highly associated with an 
outcome, especially with large sample sizes, but still have very poor diagnostic accuracy. 
The prevalence of CAD is low compared to the high prevalence of a mildly elevated CRP, 
thus the positive predictive values are low in the general population.[61] Given the even 
lower prevalence of glaucoma, the value of CRP for a risk assessment seems limited. CRP 
will be more useful if it is mechanistically related to glaucoma, especially when its 
modulation affects the disease outcome. The range in the variation of CRP level is wide and 
can be influenced by many systemic diseases or drugs. Thus the application of using the 
systemic CRP level to evaluate patients with POAG or NTG requires more verification. 
 
 
 Authors  Study design Subjects / Ethnicity Findings 
Leibovitch et 
al. (2005) 48 
Case control study 20 NTG, 30 controls / 
Israel
NTG patients had higher 
high-sensitivity CRP level 
De Voogd et 
al. (2006) 27 
Prospective 
population-based 
cohort study
3842 patients, mean 
followed-up 6.5 years / 
Netherlands
Serum high-sensitivity CRP 
level was not an important 
risk factor for OAG 
Su et al. 
(2006) 46 
Case control study 40 NTG, 40 controls / 
Taiwan 
High-sensitivity CRP level 
did not differ between NTG 
and controls
Su et al. 
(2007) 49 
Case control study 40 NTG, 40 POAG, 40 
controls / Taiwan 
No difference in the high-
sensitivity CRP level 
between NTG, POAG and 
controls
Su et al. 
(2008) 47 
Case control study 30 NTG, 30 POAG, 30 
controls / Taiwan 
High-sensitivity CRP level 
did not differ between NTG, 
POAG and controls 
Choi (2009) 50 Case control study 38 NTG, 38 controls / 
Korea 
No difference in the high-
sensitivity CRP level 
between NTG and controls 
 
CRP: C-reactive protein, NTG: normal-tension glaucoma, OAG: open-angle glaucoma, POAG: primary 
open-angle glaucoma 
 
Table 1. Summary of the findings of the studies evaluating serum CRP levels in glaucoma 
patients 
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